Atopic dermatitis, also known as atopic eczema, is a chronic pruritic skin condition affecting approximately 17.8 million persons in the United States. It can lead to significant morbidity. A simplified version of the U.K. Working Party’s Diagnostic Criteria can help make the diagnosis. Asking about the presence and frequency of symptoms can allow physicians to grade the severity of the disease and response to treatment. Management consists of relieving symptoms and lengthening time between flare-ups. Regular, liberal use of emollients is recommended. The primary pharmacologic treatment is topical corticosteroids. Twice-daily or more frequent application has not been shown to be more effective than once-daily application. A maintenance regimen of topical corticosteroids may reduce relapse rates in patients who have recurrent moderate to severe atopic dermatitis. Pimecrolimus and tacrolimus are calcineurin inhibitors that are recommended as second-line treatment for persons with moderate to severe atopic dermatitis and who are at risk of atrophy from topical corticosteroids. Although the U.S. Food and Drug Administration has issued a boxed warning about a possible link between these medications and skin malignancies and lymphoma, studies have not demonstrated a clear link. Topical and oral antibiotics may be used to treat secondary bacterial infections, but are not effective in preventing atopic dermatitis flare-ups. The effectiveness of alternative therapies, such as Chinese herbal preparations, homeopathy, hypnotherapy/biofeedback, and massage therapy, has not been established.

The goal of the current study is to ascertain the physicochemical characteristics of the broad-spectrum antifungal drug Posaconazole by a thorough preformulation assessment. Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) were used to validate the drug’s identity. The results showed distinctive peaks that were in agreement with standard standards and a melting temperature of 166°C. Beer-Lambert’s law was confirmed by UV spectroscopy, which found a λmax at 266 nm in phosphate buffer pH 6.8 with linearity in the 10–80 μg/mL range. Microscopy-based particle size measurement showed a mean diameter of 1.65–1.85 µm, and solubility tests verified strong solubility in ethanol and DMSO and moderate solubility in water. A 0.28 partition coefficient indicated a small amount of hydrophilia. These results provide credence to the choice of appropriate use Posaconazole’s future dosage form development, especially in formulations like suppositories.

Monoclonal antibodies (mAbs) now dominate the global biologics landscape, with sustained clinical and commercial impact across oncology, immunology, and infectious disease. Ensuring reliable quality, safety, and efficacy throughout development and lifecycle management depends on a rigorous Chemistry, Manufacturing, and Controls (CMC) framework. This review provides a detailed, comparative synthesis of international CMC expectations for mAbs, anchored in International Council for Harmonisation (ICH) guidelines—Q5A(R2) (viral safety), Q5C (stability), Q6B (specifications), Q8(R2), Q9(R1), Q10, Q11, Q12, and the analytical pair Q14/Q2(R2)—and complemented by U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidances. We elaborate practical strategies for CQA-driven product and process understanding; specification setting that integrates clinical relevance, process capability, and assay variability; analytical modernization (ATP-based method development, multi-attribute methods, advanced glycoanalytics); viral safety modernization (molecular detection and orthogonal clearance validation); and Process Analytical Technology (PAT) with elements of real-time release testing (RTRT). We further examine lifecycle agility through Q12 mechanisms (Established Conditions, post-approval change management protocols) and highlight emerging directions—digital CMC models, continuous/hybrid operations, immunogenicity risk integration, and sustainability metrics. Consolidated tables and figures provide at-a-glance operational guidance to support globally harmonized submissions for mAbs.